Therapeutic Apheresis
Therapeutic Apheresis (TA) applies apheresis technology to the clinical treatment of autoimmune diseases and blood disorders by removing selected, abnormal components or cells and returning all others. HemaCare/Coral Blood Services is the leading provider of TA in the United States, and has provided such services for over 25 years.
TA services are delivered through the use of mobile units operated at the patient's bedside or in an outpatient setting. Treatments are administered by experienced hemapheresis-trained staff under the supervision of specially trained physicians. The Company has performed over 50,000 therapeutic apheresis procedures -- more than any single organization in the world.
Therapeutic Apheresis FAQs
Clinical Application
TA provides a rapid clinical response, reduces patient complications, minimizes hospital stays and reduces overall costs of medical care for many diseases. Major clinical indications for TA include:
| Hematology/Oncology |
Neurology |
Nephrology/Rheumatology |
Hyperviscosity/paraproteinemic syndromes
Cryoglobulinemia
Thrombotic thrombocytopenic purpura
Leukocytosis and Thrombocytosis
Sickle cell disease
|
Guillain-Barré syndrome
Myasthenia Gravis
Chronic inflammatory demyelinating polyneuropathy
Other periperal neuropathies
|
Goodpasture's syndrome
Severe vasculitis
Hemolytic-uremic syndrome
Multiple myeloma
Systemic Lupus Erythematosus
|
TA Services
- Plasmapheresis
- Cytapheresis (Cell depletion)
- Leukapheresis
- Plateletpheresis
- LDL cholesterol adsorption
- Erthrocytapheresis (Red Cell Exchange)
- Stem cell harvesting
- Photopheresis
Research Support
- Peripheral blood stem cell collections
- Leukapheresis
- Plateletpheresis
- Blood sample collections
- Disease state human biological products
- Therapeutic exchange plasma
Regulatory Compliance
TA services are delivered by a staff with extensive training in therapeutic apheresis. Under the direction of medical directors, the HemaCare/Coral Blood Services Quality Assurance Program is based upon guidelines developed by the American Society for Apheresis and the American Association of Blood Banks.
Compliance is assured with the broad-ranging clinical and technical standards, as defined by multiple agencies, including:
- Food and Drug Administration (FDA)
- American Association of Blood Banks (AABB)
- Joint Commission for the Accreditation of Healthcare Organizations (JCAHO)
- College of American Pathologists (CAP)
- International Society for Hematotherapy and Graft Engineering (ISHAGE)
- Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT)
- Applicable State Departments of Health
Support Services
Medical Consultation
- Melanie Osby, M.D., National Medical Director
- David Ciavarella, M.D., Regional Medical Director, Mid-Atlantic
Region
- Jacquelyn Hedlund, M.D., Regional Medical Director, New England
Region
Medical Consultation or Reimbursement Assistance
800-827-5642
Clinical Library
Contact us for more information
To learn more about Therapeutic Apheresis, contact us.
|
